News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Breaking Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program
Medicus Pharma Ltd. is set to present at Biotech Showcase 2026, highlighting the upcoming readout of its Phase 2 SkinJect clinical data. This presentation underscores the company's strategic focus on advancing select programs through proof-of-concept and pursuing strategic partnerships.
Latest News
Fierce Biotech Week 2026: Key Insights and Highlights
Fierce Biotech Week 2026 delivered critical updates on gene therapy, mRNA platforms, and regulatory shifts from the FDA and EMA. This article provides key takeaways, implications for BD teams and investors, and a FAQ section.
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
FDA Flashback: Key Breast Cancer Decisions from April 2026
April 2026 brought pivotal FDA actions in breast cancer, including an ODAC split vote on AstraZeneca's candidate and a breakthrough device designation. This article analyzes the decisions, their competitive impact, and what pharma teams should watch next.
HaloMD Lawsuit Update: Highmark Health Alleges 'Sham Letter' and Misleading Data in No Surprises Act Dispute
Highmark Health has filed a lawsuit against HaloMD, alleging the No Surprises Act middleman used a 'sham letter' and misleading data to extract inflated payments. This is the fourth such lawsuit from an insurer, highlighting growing tensions over arbitration abuse.
AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma
The FDA approved AstraZeneca and Daiichi Sankyo's Datroway (Dato-DXd) as a first-line treatment for triple-negative breast cancer on May 1, 2026. This article provides key takeaways, regulatory details, and strategic implications for pharma decision-makers.
STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
Structured plan for STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patients
The Military's Role in the Rising Tide of Eating Disorders
Military service members and veterans exhibit higher rates of eating disorders compared to the general population, a trend linked to specific psychological and environmental factors within the armed forces. These conditions carry significant mortality risks and have implications for veteran healthcare and disability.
FDA Blueprint Aims to Reduce Regulatory Risks for Animal Testing Alternatives
The FDA has released a blueprint to reduce regulatory risks associated with alternatives to animal testing, signaling a significant shift in drug development and regulatory pathways. This initiative aims to streamline the adoption of new approach methodologies (NAMs), potentially accelerating drug approvals and influencing investment strategies.
China’s Rise in Drug Development Looms Over U.S. Oncology Market
Structured plan for China’s Rise in Drug Development Looms Over U.S. Oncology Market
FDA Declines Guidance on Foreign Drug Imports: Impact on Pharma BD and Investors
The FDA's decision not to issue specific guidance on foreign drug imports leaves the pharmaceutical industry navigating a complex regulatory landscape. This update impacts market strategies, compliance, and investment considerations.
Ophthalmology Pipeline Milestones for Q2 2026: Key Catalysts and Investor Insights
Q2 2026 is poised to be a pivotal quarter for the ophthalmology pipeline, with several key clinical trial readouts and potential regulatory decisions on the horizon. These milestones will significantly influence market dynamics and strategic investment for pharmaceutical companies.
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Vir Biotechnology is undergoing significant leadership changes post-AGM, with a board reshuffle and key governance votes set to influence its strategic direction. Investors and pharmaceutical BD teams should monitor these developments for potential shifts in clinical trial focus and market positioning.
Real-World Data from EHRs and Claims: Strengths, Limitations, and Regulatory Impact
Real-world data (RWD) from Electronic Health Records (EHRs) and claims offers significant value for pharmaceutical research and regulatory submissions. However, understanding its inherent strengths and limitations is crucial for effective utilization.
The Common Fund Data Ecosystem (CFDE)
Structured plan for The Common Fund Data Ecosystem (CFDE)
Physician-Led Patient Education: A Strategy to Mitigate the Gross-to-Net Squeeze
The widening gap between gross and net sales, known as the gross-to-net (GTN) bubble, poses a significant challenge for pharmaceutical manufacturers. This article examines how physician-led patient education can serve as a strategic tool to mitigate this erosion.
A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
Structured plan for A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities in 2024
The monoclonal antibody (mAb) market has transformed modern medicine, offering improved safety and effectiveness for various indications. However, persistently high prices present a significant challenge, alongside evolving innovation landscapes.
Opinion: The medical-billing AI arms race between providers and insurance
Structured plan for Opinion: The medical-billing AI arms race between providers and insurance
Opinion: The Amish Way of Healthcare Offers Lessons for Public Health
The Amish community approaches healthcare with a unique perspective, prioritizing faith and community support alongside medical interventions. Understanding their cultural beliefs and practices is crucial for public health initiatives aiming for greater cultural sensitivity and effectiveness.
NIH Funding Cuts Hamper Ebola Preparedness and Global Health Security
Recent cuts to the National Institutes of Health (NIH) have significantly weakened the network established to respond to infectious disease outbreaks, including Ebola. This reduction in funding and infrastructure compromises the United States' and global capacity to effectively manage future health crises.